Community based, emerging issue
There is broad agreement among experts that women with very high risk for ovarian cancer should undergo risk-reducing removal of their ovaries and fallopian tubes (also known as risk-reducing salpingo-oophorectomy, or RRSO), the timing of surgery depends on the genetic mutation. High risk women who are not ready to undergo surgery are sometimes followed with high risk screening consisting of CA125 and transvaginal ultrasound. These tests are not very accurate; false positive/negative tests are common. Even with screening, most women who develop ovarian cancer are not found at an early enough stage to improve their survival. Newer tests have been developed to try to detect ovarian cancer at an earlier stage. These tests have not been studied for screening of high risk women. This research questions proposes designing a study to see if the addition of a new blood test to current screening guidelines improves early detection of ovarian cancer.
Our Steering Committee and Research Work Group gave this study a prioritization score
of 2.95 out of 4 points, meaning this is a medium-high priority study.
Our Executive Committee and research team considered the feasibility of this
study through ABOUT as Low.
Recommend roll back to Assessment Phase
Our Steering Committee prioritizes questions based on four parameters on a scale from 1-4. Here are the average scores:
Our Executive Committee scored feasibility as low->medium based on the following considerations
Previvors/High risk people
People with a BRCA mutation
People with an ATM, PALB2, PTEN, or other mutation that increases cancer risk
People with Lynch Syndrome
People at high risk for breast cancer
People at high risk for ovarian cancer
People who are newly diagnosed with cancer